-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

Benzinga·10/13/2026 16:38:50
Listen to the news
TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $105 to $130.